Home Cart Sign in  
Chemical Structure| 464192-28-7 Chemical Structure| 464192-28-7

Structure of 464192-28-7

Chemical Structure| 464192-28-7

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of [ 464192-28-7 ]

CAS No. :464192-28-7
Formula : C4H2BrNOS
M.W : 192.03
SMILES Code : C1=C(C=O)SC(=N1)Br
MDL No. :MFCD03788567
InChI Key :DJUWIZUEHXRECB-UHFFFAOYSA-N
Pubchem ID :2773259

Safety of [ 464192-28-7 ]

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H317-H319
Precautionary Statements:P280-P305+P351+P338

Computational Chemistry of [ 464192-28-7 ] Show Less

Physicochemical Properties

Num. heavy atoms 8
Num. arom. heavy atoms 5
Fraction Csp3 0.0
Num. rotatable bonds 1
Num. H-bond acceptors 2.0
Num. H-bond donors 0.0
Molar Refractivity 35.2
TPSA ?

Topological Polar Surface Area: Calculated from
Ertl P. et al. 2000 J. Med. Chem.

58.2 Ų

Lipophilicity

Log Po/w (iLOGP)?

iLOGP: in-house physics-based method implemented from
Daina A et al. 2014 J. Chem. Inf. Model.

1.14
Log Po/w (XLOGP3)?

XLOGP3: Atomistic and knowledge-based method calculated by
XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry

1.77
Log Po/w (WLOGP)?

WLOGP: Atomistic method implemented from
Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.

1.72
Log Po/w (MLOGP)?

MLOGP: Topological method implemented from
Moriguchi I. et al. 1992 Chem. Pharm. Bull.
Moriguchi I. et al. 1994 Chem. Pharm. Bull.
Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.

-0.1
Log Po/w (SILICOS-IT)?

SILICOS-IT: Hybrid fragmental/topological method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

3.0
Consensus Log Po/w?

Consensus Log Po/w: Average of all five predictions

1.5

Water Solubility

Log S (ESOL):?

ESOL: Topological method implemented from
Delaney JS. 2004 J. Chem. Inf. Model.

-2.54
Solubility 0.551 mg/ml ; 0.00287 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble
Log S (Ali)?

Ali: Topological method implemented from
Ali J. et al. 2012 J. Chem. Inf. Model.

-2.61
Solubility 0.471 mg/ml ; 0.00245 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble
Log S (SILICOS-IT)?

SILICOS-IT: Fragmental method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

-2.1
Solubility 1.53 mg/ml ; 0.00798 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble

Pharmacokinetics

GI absorption?

Gatrointestinal absorption: according to the white of the BOILED-Egg

High
BBB permeant?

BBB permeation: according to the yolk of the BOILED-Egg

Yes
P-gp substrate?

P-glycoprotein substrate: SVM model built on 1033 molecules (training set)
and tested on 415 molecules (test set)
10-fold CV: ACC=0.72 / AUC=0.77
External: ACC=0.88 / AUC=0.94

No
CYP1A2 inhibitor?

Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.83 / AUC=0.90
External: ACC=0.84 / AUC=0.91

Yes
CYP2C19 inhibitor?

Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.80 / AUC=0.86
External: ACC=0.80 / AUC=0.87

No
CYP2C9 inhibitor?

Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)
and tested on 2075 molecules (test set)
10-fold CV: ACC=0.78 / AUC=0.85
External: ACC=0.71 / AUC=0.81

No
CYP2D6 inhibitor?

Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)
and tested on 1068 molecules (test set)
10-fold CV: ACC=0.79 / AUC=0.85
External: ACC=0.81 / AUC=0.87

No
CYP3A4 inhibitor?

Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)
and tested on 2579 molecules (test set)
10-fold CV: ACC=0.77 / AUC=0.85
External: ACC=0.78 / AUC=0.86

No
Log Kp (skin permeation)?

Skin permeation: QSPR model implemented from
Potts RO and Guy RH. 1992 Pharm. Res.

-6.21 cm/s

Druglikeness

Lipinski?

Lipinski (Pfizer) filter: implemented from
Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev.
MW ≤ 500
MLOGP ≤ 4.15
N or O ≤ 10
NH or OH ≤ 5

0.0
Ghose?

Ghose filter: implemented from
Ghose AK. et al. 1999 J. Comb. Chem.
160 ≤ MW ≤ 480
-0.4 ≤ WLOGP ≤ 5.6
40 ≤ MR ≤ 130
20 ≤ atoms ≤ 70

None
Veber?

Veber (GSK) filter: implemented from
Veber DF. et al. 2002 J. Med. Chem.
Rotatable bonds ≤ 10
TPSA ≤ 140

0.0
Egan?

Egan (Pharmacia) filter: implemented from
Egan WJ. et al. 2000 J. Med. Chem.
WLOGP ≤ 5.88
TPSA ≤ 131.6

0.0
Muegge?

Muegge (Bayer) filter: implemented from
Muegge I. et al. 2001 J. Med. Chem.
200 ≤ MW ≤ 600
-2 ≤ XLOGP ≤ 5
TPSA ≤ 150
Num. rings ≤ 7
Num. carbon > 4
Num. heteroatoms > 1
Num. rotatable bonds ≤ 15
H-bond acc. ≤ 10
H-bond don. ≤ 5

2.0
Bioavailability Score?

Abbott Bioavailability Score: Probability of F > 10% in rat
implemented from
Martin YC. 2005 J. Med. Chem.

0.55

Medicinal Chemistry

PAINS?

Pan Assay Interference Structures: implemented from
Baell JB. & Holloway GA. 2010 J. Med. Chem.

0.0 alert
Brenk?

Structural Alert: implemented from
Brenk R. et al. 2008 ChemMedChem

1.0 alert: heavy_metal
Leadlikeness?

Leadlikeness: implemented from
Teague SJ. 1999 Angew. Chem. Int. Ed.
250 ≤ MW ≤ 350
XLOGP ≤ 3.5
Num. rotatable bonds ≤ 7

No; 1 violation:MW<1.0
Synthetic accessibility?

Synthetic accessibility score: from 1 (very easy) to 10 (very difficult)
based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,
trained on 12'782'590 molecules and tested on 40 external molecules (r2 = 0.94)

2.42

Application In Synthesis of [ 464192-28-7 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 464192-28-7 ]

[ 464192-28-7 ] Synthesis Path-Downstream   1~5

  • 1
  • [ 464192-28-7 ]
  • [ 219735-99-6 ]
  • [ 960605-20-3 ]
YieldReaction ConditionsOperation in experiment
EXAMPLE 47; The mixture of <strong>[219735-99-6]2-chloro-4-methoxyphenyl boronic acid</strong> (372 mg), 2-bromo-5- formylthiazole(576 mg), sodium bicarbonate (6 mL, 1 M), dioxane (6 mL) and palladium tetrakistriphenylphosphine (30 mg) was heated at 1000C for 4 hours. The mixture was filtered through celite and diluted with ethyl acetate (100 mL) and washed with water (100 mL) followed by brine (50 mL). The organic fraction was dried with sodium sulfate and concentrated in vacuo to give the coupled product as a brown solid. To a solution of trimethyl phosphonoacetate (146 mg) in 5 mL of THF was added n-butyllithium (0.59 mL, 1.6 M in hexane) at O0C. The resulting solution was stirred at this temperature for 30 min. To this solution was added a THF solution (5 mL) of the above intermediate aldehyde (170 mg). The mixture was slowly warmed to rt and stirred for 2 hours. After quenching the mixture was water, the mixture was extracted with ethyl acetate, dried with sodium sulfate and concentrated in vacuo to give the enoate as a brown oily solid. To this enoate (83 mg) was added 5 mL of EPO <DP n="53"/>THF:MeOH:water (3:1:1) followed by LiOH (2 mL, 1 M). The mixture was stirred at rt for 5 hours. After acidified with concentrated HCl until pH = 4, the slurry was extracted with 30% isopropanol in chloroform, dried with sodium sulfate and concentrated in vacuo to give the enoic acid as a yellow solid. To this enoic acid (100 mg) was added toluene (5 mL) and thionyl chloride (2 mL). The mixture was heated to reflux for 1 hour and the solvent was distilled off under reduced pressure. The residue was taken up with toluene (5 mL) and to it was added anthranilic acid methyl ester (74 mg). The resulting mixture was heated to reflux for additional 1 hour. The solvent was removed and the residue was taken up with DMSO (6 mL). Only part of solid dissolved, the remaining solid was filtered and LC-MS showed it was mainly the desired compound, which was taken up with methanol (18 mL). To this mixture was added tosyl hydrazide (500 mg). The mixture was heated at reflux. After one day, an additional 300 mg of tosyl hydrazide was added. After two and a half days, the resulting mixture was concentrated and dissolved in acetone. The solution was directly purified by biotage (5%-25% ethyl acetate in petroleum ether) to give the anthranilide methyl ester as an oily solid. This methyl ester was dissolved in 5 mL of THF:MeOH: water (3:1:1) followed by LiOH (3 mL, 1 M). The mixture was stirred at rt for 4 hours. After Gilson purification, the acid was obtained as a white solid. To this methyl ether derivative was added 5 mL of dichloromethane and 0.23 mL of borontribromide (0.23 mL, IN in dichloromefhane) at O0C. After stirring at RT for 2h, the reaction was quenched by water at O0C. The mixture was concentrated in vacuo and then dissolved by DMSO. The DMSO solution was purified by Gilson to give Example 47 as a white solid. IH NMR (acetone-d6, 500 MHz) delta 11.42 (s, IH), 8.56 (d, IH), 8.07 (d, IH), 7.77 (d, IH), 7.70 (s, IH), 7.56 (t, IH), 7.15 (t, IH), 6.95 (d, IH), 6.84 (dd, IH), 3.34 (t, 2H), 2.88 (t, 2H); LCMS m/z 401 (M-I), 403 (M++l).
  • 2
  • [ 1003-61-8 ]
  • [ 464192-28-7 ]
YieldReaction ConditionsOperation in experiment
69.13% With tert.-butylnitrite; copper(I) bromide; In acetonitrile; at 25℃; for 5h;Inert atmosphere; Under N2 protection,250mLIn a two-necked flask, tert-butyl nitrite (4.8 g, 47 mmol) and copper bromide (8.2 g, 40 mmol) and anhydrous acetonitrile (180 mL) were added, and the mixture was stirred at 25 C for 0.5 h.The compound <strong>[1003-61-8]2-aminothiazole-5-carbaldehyde</strong> (4.0 g, 31 mmol) was dissolved in anhydrous acetonitrile (30 mL) and slowly added dropwise to the above solution.The reaction was stirred at 25 C for 12.0 h. concentrate,Add ethyl acetate (200 mL),The organic layer was washed once with saturated brine (60 mL).Dry anhydrous sodium sulfate (20g), concentrated,4.12 g of a red solid were obtained in a yield: 69.13%.
With tert.-butylnitrite; copper(ll) bromide; In acetonitrile; at 20℃; for 4h; 2-Amino-1, 3-THIAZOLE-5-CARBOXALDEHYDE (13.78 g, 0.108 mol, 1 eq) in acetonitrile (200 mL) (SLURRY) was added portionwise to a stirred suspension of CuBr2 (36.03 g, 0.129 mol) and t-butyl nitrite (19 mL, 0.161 mL) in acetonitrile (550 mL). The reaction was stirred at room temperature for 4 hours then evaporated to give a solid. This was treated with ethyl acetate (400 mL) and 2M HCI (400 mL). Water (200 mL), brine (100 mL) and ethyl acetate (200 mL) were added. The phases were separated. The aqueous phase was extracted with ethyl acetate (250 mL). The combined organic layers were dried (MGS04) and evaporated to give the title compound. 'H NMR (CDCI3) : 8 9.97 (1H, s), 8.19 (1H, s)
Compounds 85 and 86 were synthesized by using the materials that have a substituent corresponding to these compounds, according to the following production scheme.
  • 3
  • [ 464192-28-7 ]
  • [ 191162-40-0 ]
  • [ 1248681-42-6 ]
YieldReaction ConditionsOperation in experiment
With sodium carbonate;tetrakis(triphenylphosphine) palladium(0); In 1,2-dimethoxyethane; water; at 20℃;Inert atmosphere; Production Example 1; 2-( 1 -Methyl- lH-indol-2-yl)- 1 ,3-thiazole-5-carbaldehyde; A dimethoxyethane solution (15 mL) of commercially available ( 1 -methyl- lH-indol- 2-yl)boronic acid (328 mg), commercially available 2-bromo-l,3-thiazole-5-carbaldehyde (300 mg), tetrakis(triphenylphosphine)palladium(0) (181 mg), and 1 M sodium carbonate aqueous solution (4.7 mL) was stirred overnight at room temperature in a nitrogen atmosphere. The dimethoxyethane was distilled off under reduced pressure, and the resulting residue was extracted with chloroform, and dried over anhydrous magnesium sulfate. The solvent was distilled off under reduced pressure, and the resulting residue was purified by silica gel column chromatography (hexane:ethyl acetate = 3:2) to give the title compound (160 mg) as a pale yellow solid.
With sodium carbonate;tetrakis(triphenylphosphine) palladium(0); In 1,2-dimethoxyethane; water; at 20℃;Inert atmosphere; A dimethoxyethane solution (15 mL) of commercially available <strong>[191162-40-0](1-methyl-1H-indol-2-yl)boronic acid</strong> (328 mg), commercially available 2-bromo-1,3-thiazole-5-carbaldehyde (300 mg), tetrakis(triphenylphosphine)palladium(0) (181 mg), and 1 M sodium carbonate aqueous solution (4.7 mL) was stirred overnight at room temperature in a nitrogen atmosphere. The dimethoxyethane was distilled off under reduced pressure, and the resulting residue was extracted with chloroform, and dried over anhydrous magnesium sulfate. The solvent was distilled off under reduced pressure, and the resulting residue was purified by silica gel column chromatography (hexane:ethyl acetate=3:2) to give the title compound (160 mg) as a pale yellow solid.
  • 4
  • [ 464192-28-7 ]
  • [ 1765-93-1 ]
  • [ 914348-80-4 ]
YieldReaction ConditionsOperation in experiment
88% With tetrakis(triphenylphosphine) palladium(0); sodium carbonate; In ethanol; toluene; at 85℃; for 6h;Inert atmosphere; To a solution of 2-bromothiazole-5-carbaldehyde (5.0 g, 26.04 mmol) in toluene (150 mL) and ethanol (75 mL) was added (4-fluorophenyl)boronic acid (7.29 g, 52.08 mmol), 2M sodium carbonate solution (73.58 mL), Pd(PPh3)4 (1.5 g, 1.3 mmol) under argon atmosphere. The resulting mixture was heated at 85C for 6 h. The reaction mixture was concentrated under reduced pressure, the residue was diluted with water (150 mL), and extracted with ethyl acetate (5 x 500 mL). The organic layer was dried over Na2S04, filtered and concentrated under reduced pressures to obtain crude product. The crude product was purified by Combiflash chromatography (Mobile phase: 10% ethyl acetate in hexane) to give 2-(4- fluorophenyl)thiazole-5-carbaldehyde as off-white solid (200 mg, 88% yield). IH NMR (400 MHz, DMSO-d6): delta 10.06 (s, IH), 8.74 (s, IH), 8.14-8.11 (m, 2H), 7.39 (t, 2H); LC-MS m/z calculated for [M+H]+ 208.02, found 207.9
  • 5
  • [ 464192-28-7 ]
  • [ 80041-89-0 ]
  • [ 207675-84-1 ]
 

Historical Records

Technical Information

Categories

Related Functional Groups of
[ 464192-28-7 ]

Bromides

Chemical Structure| 848499-31-0

A240216 [848499-31-0]

2-Bromo-thiazole-5-carboxamide

Similarity: 0.88

Chemical Structure| 1161776-13-1

A170903 [1161776-13-1]

1-(2-Bromothiazol-5-yl)ethanone

Similarity: 0.85

Chemical Structure| 41731-23-1

A112011 [41731-23-1]

2-Bromo-5-methylthiazole

Similarity: 0.84

Chemical Structure| 54045-76-0

A138757 [54045-76-0]

2-Bromothiazole-5-carboxylic acid

Similarity: 0.82

Chemical Structure| 139669-95-7

A153924 [139669-95-7]

2,4-Dibromothiazole-5-carbaldehyde

Similarity: 0.80

Aldehydes

Chemical Structure| 139669-95-7

A153924 [139669-95-7]

2,4-Dibromothiazole-5-carbaldehyde

Similarity: 0.80

Chemical Structure| 1003-32-3

A236596 [1003-32-3]

Thiazole-5-carboxyaldehyde

Similarity: 0.78

Chemical Structure| 1003-60-7

A129997 [1003-60-7]

2-Methylthiazole-5-carbaldehyde

Similarity: 0.68

Chemical Structure| 82294-70-0

A210163 [82294-70-0]

4-Methylthiazole-5-carbaldehyde

Similarity: 0.66

Chemical Structure| 1003-61-8

A160589 [1003-61-8]

2-Aminothiazole-5-carbaldehyde

Similarity: 0.66

Related Parent Nucleus of
[ 464192-28-7 ]

Thiazoles

Chemical Structure| 848499-31-0

A240216 [848499-31-0]

2-Bromo-thiazole-5-carboxamide

Similarity: 0.88

Chemical Structure| 1161776-13-1

A170903 [1161776-13-1]

1-(2-Bromothiazol-5-yl)ethanone

Similarity: 0.85

Chemical Structure| 41731-23-1

A112011 [41731-23-1]

2-Bromo-5-methylthiazole

Similarity: 0.84

Chemical Structure| 54045-76-0

A138757 [54045-76-0]

2-Bromothiazole-5-carboxylic acid

Similarity: 0.82

Chemical Structure| 139669-95-7

A153924 [139669-95-7]

2,4-Dibromothiazole-5-carbaldehyde

Similarity: 0.80